us clinical guidance

Bacterial vaginosis

CDC diagnosis and treatment of symptomatic bacterial vaginosis with the 2025 ACOG recurrent-BV partner-therapy update.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with vaginal odor, discharge or test findings consistent with bacterial vaginosis, including pregnancy. Asymptomatic screening, postoperative prophylaxis and recurrent disease in complex immunocompromise require their own evidence and obstetric or specialty context.
sources for this section:CDC BV 2021ACOG BV update 2025

The Bottom Line

  • Diagnose symptomatic bacterial vaginosis with validated clinical or laboratory criteria; history alone cannot reliably distinguish BV from candidiasis, trichomoniasis or cervicitis.
  • Treat symptomatic BV with a CDC-recommended oral or intravaginal regimen selected from pregnancy, allergy, tolerance, interactions, cost and patient preference.
  • Test for HIV and other sexually transmitted infections according to exposure and screening recommendations because BV is associated with increased acquisition risk.
  • For recurrent symptomatic BV, discuss suppressive strategies and the 2025 ACOG update on concurrent sexual-partner therapy rather than repeating short courses without a recurrence plan.
  • Use shared decision-making for partner treatment and follow current state law; ACOG does not make expedited partner therapy an automatic substitute for partner evaluation.
sources for this section:CDC BV 2021ACOG BV update 2025

Practical clinical workflow

1
Ask about odor, discharge, irritation, bleeding, pregnancy, sexual partners and practices, douching, intravaginal products, prior BV, antibiotics and self-treatment.
2
Examine when appropriate and use pH, amine testing, microscopy, Gram stain or a validated molecular test in a symptomatic patient, while evaluating cervicitis and pelvic pain.
3
Select a CDC regimen, explain adherence and product-specific condom effects, and avoid an unsupported alcohol prohibition when using metronidazole.
4
For recurrence, confirm the diagnosis, reassess trichomoniasis and other causes, review prior regimens and discuss suppressive or concurrent-partner options supported by the current sources.
5
Arrange obstetric coordination for symptomatic BV in pregnancy and targeted follow-up when symptoms persist, recur or treatment adverse effects occur.
sources for this section:CDC BV 2021ACOG BV update 2025

Safety boundaries and escalation

  • Fever, significant pelvic pain, cervical-motion or adnexal tenderness, pregnancy pain or bleeding requires assessment for PID, ectopic pregnancy or another urgent diagnosis.
  • Do not treat a positive molecular result without compatible symptoms or a source-supported screening indication; detection and disease are not synonymous.
  • Clindamycin vaginal products can weaken latex or rubber barriers for a product-specific interval, so counseling must match the exact formulation.
  • Recurrent BV causes substantial distress; avoid blame, coercive partner assumptions or unsupported claims that recurrence proves infidelity.
sources for this section:CDC BV 2021ACOG BV update 2025

Localization

CDC 2021 remains the core US treatment source, but the December 2025 ACOG focused update changes the conversation about concurrent partner therapy for recurrent symptomatic BV. State EPT law and local sexual-health services govern implementation.
sources for this section:CDC BV 2021ACOG BV update 2025

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionSexually Transmitted Infections Treatment Guidelines, 2021 — Bacterial VaginosisMMWR 2021;70(No. RR-4) · published 2021-07-23 · accessed 2026-08-20
    view source
  2. American College of Obstetricians and GynecologistsConcurrent Sexual Partner Therapy to Prevent Bacterial Vaginosis RecurrenceDOI 10.1097/AOG.0000000000006102 · published 2025-10-16 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.